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1. Introduction
The importance of andro-
gens for the human body is 
due to the finding of androgen 
receptors in the cells of most 
tissues: the mammary gland, 
the heart, blood vessels, the 
digestive tract, the lungs, the 
central nervous system, and 
the peripheral nerves, the skin, 
the musculoskeletal system, 
the bone marrow, the uterus, 
ovaries, external genital or-
gans, adipose tissue [1]. There-
fore, deficiency of androgens 
in women can be manifested 
not only by sexual disorders 
(decreased libido, sexual plea-
sure and orgasm), but also 
other pathological symptoms 
including mood changes (irri-
tability, anxiety, depression), 
poor health, physical weakness, 
changes in cognitive function, 
illness Alzheimer’s disease, 
memory impairment, chronic 
pain, urinary tract disorder, re-
productive disorders [2].
Known effects of androgens 
on the state of muscle and mu-
cous membranes of the pelvic 
f loor and perineum in wom-
en: the level of estrogen in the 
blood affects the expression of 
androgen receptors in the wom-
an’s vagina. It is shown that the 
density of androgen receptors 
with age significantly decrea- 
ses [3].
The consensus of the An En-
docrine Society Clinical Practice 
on female androgen deficiency 
in Princeton, USA, was proposed 
the term «female androgen defi-
ciency,» which was defined as a 
group of clinical manifestations 
at normal estrogen levels and 
lowered testosterone levels. Ac-
cordingly, this consensus, the 
deteriorating state of health and 
dystrophic mood, permanent 
weakness and changes in sex-
ual function, in that pure de-
crease in libido and the absence 
of orgasm, were considered as 
typical signs of syndrome of 
androgen deficiency. From that 
point on, several double-blind, 
placebo-controlled studies have 
been performed on the use of 
testosterone in women, which 
demonstrated its efficacy and 
safety when administered in 
physiological doses [4].
Particular attention is re-
quired to study the state of the 
genitourinary system, which is 
hormone dependent, so it is ob-
vious that age-associated symp-
toms of pathological processes 
of the lower urinary tract are 
likely to be considered as a «uro-
logical mask» of the deficiency 
of sex hormones [5]. Research 
results show that sex hormones 
are capable of modulating the 
functions of the neuroreceptor 
apparatus of the bladder, both in 
men (androgens) and in women 
(estradiol, progesterone, andro-
gens). Androgens may have an 
effect on the vaginal mucus both 
via estrogen receptors by f la-
voring in estrogens and directly 
through androgen receptors, ef-
fectively alleviating the symp-
toms of urovaginal atrophy [6].
According to the literature 
[7, 8], the effects of the deficit of 
sex hormones for both sexes are 
manifested by a decrease in blood 
supply to the pelvic organs, due to 
the induction of pelvic atheroscle-
rosis, which leads to hypoxia and 
ischemia of the genitourinary sys-
tem; reduction of the diameter of 
arteries of the bladder, reduction 
of the number of small vessels and 
thinness of their walls (decrease in 
the density of microcirculation). 
On the other hand, androgens 
have anabolic effects on muscle 
tissue, the receptors for androgens 
are expressed in the muscles of 
the pelvic floor and the lower sec-
tions of the urinary tract, both in 
animals and in humans. A recent 
study showed changes in the me-
tabolism of collagen and elastin in 
the tissues of the external genitalia 
when they fall out. These changes 
relate not only to the synthesis 
of structural proteins, but also to 
the balance between the action of 
major proteolytic enzymes, such 
as metalloproteinases, which im-
pair the synthesis of the protein. 
Testosterone is a potent inhibitor 
of metalloproteinases in the tis-
sues of the uterus [9]. A strong 
reverse correlation between slow 
collagen collapse in the urogenital 
tract and levels of total and free 
blood testosterone was found in 
the group of patients, which may 
be due to the inhibition of metal-
loproteinase with this hormone 
[10, 11]. 
UROGENITAL DISORDERS IN WOMEN OF  




Department of Reproductive Medicine and Surgery
Ukrainian Scientific and Practical Center of endocrine  
surgery, endocrine transplantation of organs and tissues of  
the Ministry of Health of Ukraine
13a Klovsky descent, Kyiv, Ukraine, 01021
dles@i.ua
Abstract: According to the consensus of An Endocrine Society Clini-
cal Practice in Princeton, USA, worsening well-being and dystrophic 
mood, permanent weakness and altered sexual function, including 
libido decline and lack of orgasm, were considered as typical signs 
of androgen deficiency syndrome. Particular attention is required to 
study the state of the genitourinary system, which is hormone de-
pendent, so it is obvious that age-associated symptoms of pathologi-
cal processes of the lower urinary tract are likely to be considered as a 
"urological mask" of the deficiency of sex hormones.
Aim of the work. Identify and describe the most common urogenital 
disorders in women of reproductive age with androgen deficiency.
Materials and methods. The study was conducted at the Ukrainian 
Scientific and Practical Center of Endocrine Surgery, Endocrine or-
gans and tissues transplantation of the Ministry of Health of Ukraine 
during 2017–2018 years. A survey was conducted on 80 women of re-
productive age who had major complaints of sexual disturbances (de-
creased libido and lack of orgasm, as well as dyspareunia as the main 
manifestations of androgen deficiency in women) and 30 healthy re-
productive women without complaints of sexual dysfunction. General 
clinical methods were used (questionnaire of patients with a detailed 
study of socio-economic status, somatic, gynecological, obstetric and 
sexual history). The condition of external and internal genital organs 
was evaluated in the study of cervix and vagina in mirrors and gyne-
cological bimanual study. At the same time, batches of analyzes for 
bacteriological research and colpocytology studies were conducted. 
The “HAWK 2102 EXL” (Germany) apparatus was used for ultrasound 
examination of pelvic organs using transabdominal and transvaginal 
convection sensors with frequencies of 3.5 and 5 MHz, respectively. 
Consultation of the urologist in order to exclude organic urological 
pathology and, if necessary, cystoscopy was also done.
In the plasma of venous blood, the following hormonal indices were 
also determined by solid phase IFA, namely, content: free testoster-
one, DHEA, androstenedione, prolactin, ACTH, cortisol, FSH, LH, 
estradiol, progesterone.
Results. It was revealed after exclusion of the urologist of the organic 
pathology of the urinary tract, in 49 % (39) of the main group, there were 
disturbances of urination associated with atrophic changes in the distal 
sections of the urinary tract. The revealed signs of vulvovaginal atrophy: 
pH 6.1±0.7 in women of the main group and pH 4.3±0.5 in women of 
the control group, in addition reduction of the karyopyknotic index and 
increase of the ripening index as signs of atrophic changes in the vaginal 
mucosa and cervical canal, was detected in 70 % (56) women in the main 
group and not found in the control group. At the same time, the prolapse 
of the genitalia of mild degree in women of the main group was detected 
in 32 % (27), and in the control group, this pathology was not found.
Conclusions. Detection of these changes, which was considered 
characteristic of women in perimenopause and postmenopausal, 
makes it important and valid for the continuation of the study of 
patients with androgen deficiency, the discovery of clinical and lab-
oratory criteria for diagnosis and the development of methods for 
correcting androgen deficiency in women of all ages.
Keywords: androgen deficiency, women of reproductive age, urogenital 
disorders, urogenital atrophy, genital prolapse.
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Pathogenetic treatment of androgen deficiency is actively 
studied by many scientists in the world. A number of experi-
mental studies have shown the effectiveness of the use of an-
drogens – DHEA and testosterone in postmenopausal women 
with sexual and urogenital disorders [12]. Also, many authors 
consider the vaginal forms of DHA and testosterone (oint-
ments, creams) with a number of advantages, namely, the high 
concentration of testosterone obtained in the pelvic area when 
administered through the mucous membrane of the vagina and 
the absence of pronounced systemic effects [8, 13]. 
Proceeding from the fact that the overwhelming majority of 
studies in women with androgen deficiency were carried out in 
postmenopausal, to date, not all aspects of correction of sexual 
dysfunction and urogenital disorders of the female population 
of different age groups have not been resolved. Therefore, we 
conducted a study of urogenital disorders in women of repro-
ductive age in order to identify the main clinical manifestations 
of androgen deficiency in this age group of women.
The aim of the study is to identify and describe the most 
common urogenital disorders in women of reproductive age 
with androgen deficiency.
2. Methods
The research was conducted in the Ukrainian Scientific 
and Practical Center of Endocrine Surgery, Transplantation 
of Endocrine organs and tissues of MOH of Ukraine during 
2017–2018 years.
The study included 80 women of reproductive age who had 
major complaints of sexual disturbances (decreased libido and 
lack of orgasm, as well as dyspareunia, as the main manifesta-
tions of androgen deficiency in women) and 30 healthy women 
of reproductive age without complaints of sexual health disor-
ders. General clinical methods (questionnaire of patients with 
detailed study of socio-economic status, somatic, gynecological, 
obstetric and sexual history) were used. The condition of exter-
nal and internal genital organs was evaluated in the study of cer-
vix and vagina in mirrors and gynecological bimanual study. At 
the same time, batches of analyzes for bacteriological research 
and colpocytology studies were conducted. The “HAWK 2102 
EXL” (Germany) apparatus was used for ultrasound examina-
tion of pelvic organs using transabdominal and transvaginal 
convection sensors with frequencies of 3.5 and 5 MHz, respec-
tively. Consultation of the urologist in order to exclude organic 
urological pathology and, if necessary, cystoscopy were done.
In the plasma of venous blood, the following hormonal in-
dices were also determined by solid phase IFA, namely, content: 
free testosterone, DHEA, androstenedione, prolactin, ACTH, 
cortisol, FSH, LH, estradiol, progesterone.
3. Results
Having analyzed the data from the questionnaires and gen-
eral-clinical and gynecological examinations and excluded pa-
tients with somatic and gynecological pathology, we found that 
the deficiency of androgens in women was manifested in sexual 
disorders in 100 % (80 patients) of the main group (decreased 
libido, sexual pleasure and lack of orgasm). Other pathologi-
cal symptoms, including mood changes (irritability, anxiety, 
depression), were detected in 80 % (64 patients) of the main 
group, while in the control group only 20 % (6 women). Poor 
feeling and physical weakness after the exclusion of somatic and 
gynecological pathology were found in 67 % (54) of the main 
group and 20 % (6) of the control group. Memory impairment 
and cognitive abilities in 56 % (45) of the main group and 17 % 
(5) of the control group. 
In the analysis of urological disorders, including urinary 
incontinence, after the exclusion of the urologist of the organic 
pathology of the urinary tract, 49 % (39) of the main and 4 % 
(1) control group revealed urinary tract disorders associated 
with atrophic changes in the distal urinary tract. There are also 
known effects of androgens on pelvic floor muscle and mucous 
membranes of the external genitalia in women. To diagnose 
vulvovaginal atrophy, two main objective methods of diagnosis 
are needed: the determination of the pH of the vaginal discharge 
and the calculation of the vaginal index of ripening (the ad-
vantage of basal and basal cell layers). The study revealed a pH 
of 6.1±0.7 in women of the main group and a pH of 4.3±0.5 in 
women in the control group. In addition, the reduction of the 
karyopyknotic index and the increase of the ripening index, as 
signs of atrophic changes in the vaginal mucosa and cervical 
canal, were detected in 70 % (56) women in the main group and 
not found in the control group. At the same time, the prolapse 
of the genitalia of mild degree in women of the main group was 
detected in 32 % (27), and in the control group this pathology 
was not found.
In studying the state of hormonal homeostasis in women 
with symptoms of androgen deficiency in reproductive age, a 
study was conducted into the basal levels of gonadotropic and 
sex hormones in serum for 2–3 and progesterone – on the 21st 
day of the menstrual cycle (Table 1).
Table 1
Indicators of gonadotropic and sex hormones in serum of 
examined women before treatment (M±m) 
Hormones
Groups of examined women
main (n=80) control (n=30)
LH, mMo/ml 8.97±1.53 7.21±2.14
FSH, mMo/ml 4.67±0.54 5.17±0.72
Prl, ng/ml 19.34±2.03 10.7±2.64
E2, pg/ml 223.5±11.3 234.1±14.6
P, nmol/l 12.0±2.03 17.3±2.06
DHEA, μmol/l 46.1±8.6* 159.6±12.7
Free T, nmol/l 0.56±0.92* 1.74±0.56
SHBG nmol/l 87±24 56±35
Androstendiol, nmol/l 0.25±0.15* 3.34±0.21
ACTH, pg/ml 19.33±1.4 19.24±2.1
K, mg/dl 16.1±1.36 7.2±1.58
Note: * – the difference is significant in relation to the indicator of the 
control group (р<0.05)
4. Discussion
Despite the fact that there is still no “gold standard” for the 
detection of androgen deficiency in clinical practice, research in 
this direction is carried out. The European Endocrinology com-
munity believes that these measures are necessary to identify a 
clinically acceptable diagnosis of androgen deficiency syndrome 
based on measured parameters of androgens and the specific 
clinical effects of female androgen deficiency [14].
As a result of a study of women of reproductive age 
with confirmed low blood androgens (testosterone free 0.56± 
±0.92 nmol/l, DHEA 46.1±8.6 μmol/l, androstenedione 0.25± 
±0.15 nmol/l) it was found that, as for menopausal women, the 
clinical manifestations of androgen deficiency are as changes in 
the CNS, including mood changes (irritability, anxiety, depres-
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sion) in 80 % (64 patients) of the main group, poor health and 
physical weakness after exclusion somatic and gynecological 
pathology was detected in 67 % (54) of the main group, impaired 
memory and cognitive abilities in 56 % (45). 
In the analysis of urological disorders, including urinary 
incontinence, after exclusion by the urologist of the organic 
pathology of the urinary tract, in 49 % (39) of the main group, 
mucosal dysfunctions were associated with atrophic changes 
in the distal sections of the urinary tract. In the diagnosis of 
vulvovaginal atrophy, two main objective criteria were identi-
fied: the determination of pH of vaginal discharge in the study 
revealed a pH of 6.1±0.7 in women of the main group and a 
pH of 4.3±0.5 in women of the control group. In addition, the 
reduction of the karyopyknotic index and the increase of the 
ripening index, as signs of atrophic changes in the vaginal 
mucosa and cervical canal, were detected in 70 % (56) women 
in the main group and not found in the control group. Genital 
prolapse of mild degree in women of the major group were 
detected in 32 % (27), and in the control group this pathology 
was not detected
Based on the fact that the use of androgens leads to im-
proved sexual health and urogenital malformations in post-
menopausal women, it can be thought that they can have a 
positive effect on the status of women with low testosterone and 
decreased sexual function and before menopause [15]. Howev-
er, in comparison with the large database of postmenopausal 
studies in the literature, there is a small number of studies in 
women of the reproductive period. This makes it important and 
reasonable to continue the study of patients with androgen de-
ficiency, to identify clinical and laboratory criteria for diagnosis 
and to develop methods for correcting androgen deficiency in 
women of all ages.
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